Faeth Therapeutics Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
29
- Stock Symbol
-
FTH
- Investments
-
2
- Share Price
-
$8.70
- (As of Wednesday Closing)
Faeth Therapeutics General Information
Description
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
Contact Information
Website
www.faeththerapeutics.comCorporate Office
- 1405 Research Boulevard
- Suite 125
- Rockville, MD 20850
- United States
Corporate Office
- 1405 Research Boulevard
- Suite 125
- Rockville, MD 20850
- United States
Faeth Therapeutics Stock Performance
As of 18-Nov-2026, Faeth Therapeutics’s stock price is $8.70. Its current market cap is $225M with 25.8M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.70 | $9.04 | $7.45 - $42.14 | $225M | 25.8M | 498K | -$22.50 |
Faeth Therapeutics Financials Summary
As of 30-Sep-2026, Faeth Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 589,412 | (9,562) | (30,206) | (47,944) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (215,898) | (22,153) | (31,295) | (36,981) |
| Net Income | (211,358) | (21,085) | (30,157) | (34,101) |
| Total Assets | 178,949 | 22,902 | 45,361 | 74,374 |
| Total Debt | 145 | 1,509 | 3,845 | 6,208 |
Faeth Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Faeth Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Faeth Therapeutics Comparisons
Industry
Financing
Details
Faeth Therapeutics Competitors (69)
One of Faeth Therapeutics’s 69 competitors is Kura Oncology, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kura Oncology | Formerly VC-backed | San Diego, CA | ||||
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Xenetic Biosciences | Corporation | Framingham, MA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom |
Faeth Therapeutics Patents
Faeth Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200390902-A1 | Antibody-drug conjugates targeted at human aspartyl-(asparaginyl)-b-hydroxylase (haah) | Inactive | 22-Aug-2017 | ||
| WO-2019040537-A1 | Antibody-drug conjugates targeted at human aspartyl-(asparaginyl)-b-hydroxylase (haah) | Inactive | 22-Aug-2017 | ||
| US-20190049455-A1 | Haah and mmp-9 are complementary cancer biomarkers and predictors of metastasis when combined | Inactive | 11-Aug-2017 | ||
| WO-2019032742-A1 | Haah and mmp-9 are complementary cancer biomarkers and predictors of metastasis when combined | Inactive | 11-Aug-2017 | ||
| WO-2019032744-A1 | Haah and mmp-9 are complementary cancer biomarkers and predictors of metastasis when combined | Inactive | 11-Aug-2017 | G01N33/57585 |
Faeth Therapeutics Signals
Faeth Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Faeth Therapeutics Acquisitions (2)
Faeth Therapeutics’s most recent deal was a Merger/Acquisition with Faeth for . The deal was made on 17-Feb-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Faeth | 17-Feb-2026 | Merger/Acquisition | Drug Discovery | ||
| Alvaxa Biosciences | 19-May-2020 | Merger/Acquisition | Biotechnology |
Faeth Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.47 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Faeth Therapeutics FAQs
-
When was Faeth Therapeutics founded?
Faeth Therapeutics was founded in 1999.
-
Where is Faeth Therapeutics headquartered?
Faeth Therapeutics is headquartered in Rockville, MD.
-
What is the size of Faeth Therapeutics?
Faeth Therapeutics has 29 total employees.
-
What industry is Faeth Therapeutics in?
Faeth Therapeutics’s primary industry is Drug Discovery.
-
Is Faeth Therapeutics a private or public company?
Faeth Therapeutics is a Public company.
-
What is Faeth Therapeutics’s stock symbol?
The ticker symbol for Faeth Therapeutics is FTH.
-
What is the current stock price of Faeth Therapeutics?
As of 18-Nov-2026 the stock price of Faeth Therapeutics is $8.70.
-
What is the current market cap of Faeth Therapeutics?
The current market capitalization of Faeth Therapeutics is $225M.
-
Who are Faeth Therapeutics’s competitors?
Kura Oncology, Altimmune, Xenetic Biosciences, Sarepta Therapeutics, and Immunocore Holdings are some of the 69 competitors of Faeth Therapeutics.
-
What is Faeth Therapeutics’s annual earnings per share (EPS)?
Faeth Therapeutics’s EPS for 12 months was -$22.50.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process